Stockscreener 앱 받기
68.11
0.58%
0.39
시간 외 거래:
68.11
전일 마감가:
$67.72
열려 있는:
$67.08
하루 거래량:
690.45K
Relative Volume:
0.90
시가총액:
$3.42B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-42.25
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
-6.25%
1개월 성능:
-7.63%
6개월 성능:
+65.24%
1년 성능:
+65.80%
1일 변동 폭
$66.79
$69.26
1주일 범위
$66.79
$74.00
52주 변동 폭
$36.88
$78.54
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
68.11 | 3.48B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Responsive Playbooks and the MIRM Inflection - news.stocktradersdaily.com
Mirum to present new data on liver disease therapies at AASLD meeting - Investing.com Australia
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting - Investing News Network
Mirum to present new data on liver disease therapies at AASLD meeting By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting® - Business Wire
Is Mirum Pharmaceuticals Inc. stock overvalued by current metrics2025 Short Interest & Verified Technical Signals - newser.com
Mirum Pharmaceuticals engages at NASPGHAN 2025 Annual Meeting - Traders Union
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2025 Earnings Call Transcript - Insider Monkey
Published on: 2025-11-06 04:51:32 - newser.com
Why Mirum Pharmaceuticals Inc. stock is rated strong buy2025 Technical Overview & Consistent Profit Focused Trading Strategies - fcp.pa.gov.br
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed action2025 Momentum Check & Weekly Breakout Watchlists - newser.com
Will Mirum Pharmaceuticals Inc. stock outperform tech sector in 2025Market Sentiment Summary & Risk Controlled Stock Alerts - fcp.pa.gov.br
Is Mirum Pharmaceuticals Inc. stock supported by strong cash flowsJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Mirum Pharmaceuticals (MIRM): Discounted Valuation Reinforces Bullish Narrative on Profit Breakthrough Potential - Yahoo Finance
Citizens Maintains Mirum Pharmaceuticals (MIRM) Market Outperform Recommendation - Nasdaq
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - sharewise.com
Will Mirum Pharmaceuticals Inc. stock gain from government policies2025 Institutional Moves & Community Consensus Stock Picks - fcp.pa.gov.br
Mirum Pharmaceuticals (MIRM) Projected to Post Earnings on Tuesday - MarketBeat
Will breakout in Mirum Pharmaceuticals Inc. lead to full recovery2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
What Analysts Are Saying About Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals stock price target raised to $95 by Citizens - Investing.com Canada
Will Mirum Pharmaceuticals Inc. (08D) stock keep high P E multiplesJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
Why Mirum Pharmaceuticals Inc. stock remains undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Mirum Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Decoding Mirum Pharmaceuticals Inc (MIRM): A Strategic SWOT Insi - GuruFocus
Mirum Pharmaceuticals earnings beat by $0.20, revenue topped estimates - Investing.com Canada
Earnings Call Summary | Mirum Pharmaceuticals(MIRM.US) Q3 2025 Earnings Conference - 富途牛牛
How to build a custom watchlist for Mirum Pharmaceuticals Inc.Earnings Trend Report & Technical Buy Zone Confirmation - newser.com
Earnings call transcript: Mirum Pharmaceuticals reports Q3 2025 earnings beat By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
(MIRM) Mirum Pharmaceuticals Expects Full Year 2025 Revenue Range $500 Million$510 Million, vs. FactSet Est of $506.4 Million - MarketScreener
Earnings call transcript: Mirum Pharmaceuticals reports Q3 2025 earnings beat - Investing.com
Mirum Pharmaceuticals Lifts Guidance After LIVMARLI Sales Surge - Finimize
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings: EPS of $0.06 - GuruFocus
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q3 Revenue $133.0M, vs. FactSet Est of $130.5M - MarketScreener
Mirum Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2025 - MarketScreener
[10-Q] Mirum Pharmaceuticals, Inc. Quarterly Earnings Report | MIRM SEC FilingForm 10-Q - Stock Titan
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth - MarketScreener
[8-K] Mirum Pharmaceuticals, Inc. Reports Material Event | MIRM SEC FilingForm 8-K - Stock Titan
Mirum Pharmaceuticals Q3 2025 Earnings Preview - MSN
How currency fluctuations impact Mirum Pharmaceuticals Inc. stock2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Will Mirum Pharmaceuticals Inc. see short term momentumMarket Risk Analysis & Safe Entry Zone Tips - newser.com
Mirum Pharmaceuticals to Participate in Upcoming November 2025 Investor Conferences - BioSpace
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Investing News Network
Why analysts remain bullish on Mirum Pharmaceuticals Inc. stockAnalyst Upgrade & Smart Allocation Stock Tips - newser.com
Is it time to cut losses on Mirum Pharmaceuticals Inc.Weekly Volume Report & High Yield Equity Trading Tips - newser.com
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.44%
0.70%
자본화:
|
볼륨(24시간):